Cepheid’s Q2 revenue did not fall across the board as was originally reported; clinical product sales increased 135 percent during the period. Also, the company had around $80.5 million in marketable securities as of June 30.
 
NEW YORK (GenomeWeb News) – Cepheid yesterday reported a 7-percent drop in second-quarter revenues as products and services declined in most segments.
 
The news caused shares in the company to trade down 18.7 percent, or $1.62, to $7.05 mid-afternoon today.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.